Sun Pharma to buy Ranbaxy

Share this article:

Generics maker Sun Pharmaceutical is buying Daiichi Sankyo's generics firm Ranbaxy, which is based in India. Reuters reports that Daiichi Sankyo will get 0.8 Sun Pharma shares for each Ranbaxy share.

The news follows a slate of bad news about generics made in India, including the FDA banning products from four Ranbaxy sites. The FDA has defended generics made in India and has said it is working with the country's regulatory agency to bring up standards and manufacturing scrutiny.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Genentech shift could prove costly for hospitals

Genentech will use specialty distributors rather than wholesalers, hospitals pharmacy directors have learned.

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies